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The liver is an important target for gene transfer as it is the major synthetic organ in the body and a site of metastatic cancer spread. Long-term correction of the genetic diseases which affect the liver will require stable integration of the correcting gene into the host genome. Retrovirus-based vectors integrate into the target tissues and they are the most extensively studied vectors in animal models and clinical trials. They do however require the target cell to be mitotically active for transduction to occur.
1 Adeno-associated virus based vectors are in principle also capable of integrative gene transfer but the quantity of inserted DNA they can carry is limited. 2 The liver is a mitotically quiescent organ and to date transduction with retroviral vectors has only occurred when hepatocytes have been stimulated into mitosis either by partial hepatectomy, [3] [4] [5] prior transduction with an adenoviral vector encoding the urokinase gene, 6, 7 or growth factor administration. 8 The need for major surgery before integrative gene transfer is clinically undesirable 9, 10 and adenoviral transduction of the liver has disadvantages.
The thyroid axis is essential to liver regeneration; thyroidectomized rats fail to regenerate their livers following 11 and exogenously administered T3 can cause a surge of DNA synthesis in the intact livers of euthyroid rats. 12 Here we show that a single dose of T3 can promote cell proliferation in a third of hepatocytes without any preceding liver damage, and that this population of new hepatocytes is not eliminated. Furthermore, in the proliferative phase following T3 administration, the hepatocytes of the intact rat liver are receptive to transfection with the amphotropic retroviral vector TELCeB/AF-7. 13 We used 5-bromo-2′-deoxyuridine (BrdU), administered 1 h before death, to label S-phase nuclei and demonstrate hepatocyte proliferation. In the resting livers of normal animals 0.05 ± 0.01% (n = 4) of hepatocytes were labelled. Twenty-four hours after partial hepatectomy 35.9 ± 7.43% (n = 5) of hepatocytes were labelled, predominantly in the periportal region (Figure 1a ). Twentyfour hours following T3 administration (400 g/100 g bw) 12.4 ± 5.8% (n = 5) of hepatocytes were labelled, predominantly in the mid-zonal region of the hepatic parenchyma (Figure 1b) .
To study the fate of the population of hepatocytes which had entered S-phase, a group of 10 rats were given T3 as above, and from 21 to 51 h following this they were injected intraperitoneally with BrdU at 6-h intervals to label all hepatocytes entering S-phase. Five rats were killed at 4 days and five rats at 10 days. At 4 days, 31.7 ± 7.6% of hepatocytes were labelled with BrdU (n = 5) and 30.9 ± 6.6% were still labelled at 10 days (n = 5). Since there was no decrease in the percentage of labelled hepatocytes between 4 and 10 days after the single injection of T3, it was clear that the population of newly formed hepatocytes were not selectively deleted in comparison to those which had remained quiescent. At no time was there histological evidence of liver necrosis. However, at 4 days post-T3 there was morphological evidence of apoptotic bodies throughout the hepatic parenchyma, but these had disappeared by 10 days.
Evidence of hepatocyte necrosis following T3 administration was also sought by measuring plasma transaminases. Normal rats had a plasma alanine aminotransferase (ALT) of 63.5 ± 7.8 IU/l and an aspartate aminotransferase (AST) of 97.4 ± 19.3 (n = 5). Twenty-four hours following partial hepatectomy there was a significant rise of ALT to 300 ± 70.9 IU/l and AST to 589 ± 148.9 IU/l (n = 11) (P Ͻ 0.01). This compares to T3 treatment which resulted in a plasma ALT of 66.7 ± 19.2 IU/l and an AST of 118 ± 34.1 IU/l 24 h after injection (n = 15) (nonsignificant versus control) (Figure 2) .
We tested the hypothesis that T3 induced hyperplasia enhanced in vivo retroviral transfection. Preliminary results were obtained using the psi2-BAG retrovirus 14 as a vector: these consistently demonstrated the absence of hepatic ␤-galactosidase expression in rats that had either not received the retrovirus, or who had not undergone partial hepatectomy or T3 treatment before transduction. Hepatic ␤-galactosidase expression was seen in rats who had received either the partial hepatectomy or T3 injection before in vivo retroviral transfection. The remainder of the experiments were conducted using the TELCeB/AF-7 vector which was of a higher titre, and included a nuclear localisation sequence which enabled more accurate quantification of transduction efficiency.
Retroviral transduction 24 h after partial hepatectomy resulted in 5.2 ± 2.1% (n = 7) of hepatocytes expressing the ␤-galactosidase enzyme when animals were killed at day 11 (n = 7). The transgene was expressed mainly in the periportal region. Retroviral transduction 24 h after subcutaneous T3 administration resulted in 1.3 ± 0.5% (n = 8) of hepatocytes expressing the ␤-galactosidase enzyme at day 11. Following T3 treatment, transfected hepatocytes were mainly distributed in the mid-zonal region and were found in every lobe of the liver ( Figure  3 ). Retroviral transduction 24 h after sham T3 injection (solvent only) resulted in 0.02 ± 0.014% (n = 4) of hepatocytes being transduced. Intraportal injection of culture medium without virus 24 h after subcutaneous T3 injection resulted in no ␤-galactosidase detection. Following T3 treatment and retroviral transduction no nuclear localised ␤-galactosidase expression was detected in the heart, lung, testes, skeletal muscle or brain of any animals.
It is clear that for lasting correction of the genetic diseases that affect the liver, integration of the correcting gene into hepatocyte DNA must occur. Under normal conditions only 0.1-0.2% of hepatocytes are in S phase of the cell cycle, the remainder are in the resting or G0 phase of the cell cycle, making the liver a difficult target for gene transfer by integrating vectors. However, the liver has a remarkable regenerative capacity and following partial hepatectomy (when two-thirds of the liver is resected) the liver can regrow to its original size in approximately 10 days. Following partial hepatectomy there is a surge in DNA synthesis which is maximal at 24 h; as would be anticipated this corresponds to the time when the liver is most receptive to transduction with retroviral vectors. 3 Clearly this surgery is unacceptable in routine clinical practice and this has stimulated the search for other less damaging ways of inducing liver proliferation before integrative gene transfer.
A method for inducing DNA synthesis in hepatocytes without surgery has been to transduce the liver with an adenovirus-based vector encoding the urokinase gene; 6 unfortunately this caused a coagulopathy in the animals which received the vector. When a nuclear localisation signal was included in the urokinase gene, the surge in DNA synthesis was seen in recipient rats without a coagulopathy. This regeneration permitted their livers to be transduced by retroviral vectors in vivo. 7 More recently keratinocyte growth factor has been administered to mice to induce hepatocyte proliferation, enabling 2% of their hepatocytes to be transduced in vivo by retroviral vectors. 10 Liver regeneration depends upon an intact thyroid axis; the livers of thyroidectomized rats that have undergone partial hepatectomy fail to regenerate. Subcutaneous tri-iodothyronine given to normal rats is able to induce a surge in DNA synthesis which, as after partial hepatectomy, is maximal at 24 h. 12 This response is accompanied by an increased expression of hepatic c-Haras and TGF␣ mRNA at 24 h, followed by increased expression of TGF␤ mRNA at 72 h, changes which mirror those seen following partial hepatectomy. The DNA synthetic response to T3 is specific to the liver, it is not seen in kidney or gut and it is non-fatiguable, ie the same response to T3 can be seen following repeat administration.
In the first part of the study, we set out to quantify the proportion of hepatocytes induced into DNA synthesis by T3 and establish the stability of these cells by following their fate after BrdU labelling. BrdU is a thymidine analogue which is incorporated into cell nuclei during Sphase, where it remains stably bound in the nucleus and can be recognised immunohistochemically using monoclonal antibodies. 15 By administering BrdU intraperitoneally 6 hourly from 21 to 51 h after T3 administration we aimed to label all of the hepatocytes induced into the cell cycle by the hormone. We demonstrated that following a single subcutaneous dose of the physiological hormone tri-iodothyronine, one-third of hepatocytes in the intact liver became labelled with BrdU, most importantly the proportion of labelled hepatocytes was the same at 4 days after T3 injection (when the liver is completing the wave of hepatocyte proliferation and is actively deleting excess hepatocytes by apoptosis) as at 10 days after T3 injection (when the liver has completed its wave of apoptosis and has a stable hepatocyte population). This demonstrates that the population of hepatocytes induced into cell cycle are at no greater risk of compensatory deletion through apoptosis than those which have remained quiescent, an important feature for any cell which is to be transduced with the aim of longterm gene expression.
The percentage of hepatocytes transduced by the reporter gene following T3 treatment was less than that following partial hepatectomy, however the transduced gene was distributed evenly throughout the liver which, of course, was three times the size of the partial hepatectomy remnant. Thus, the absolute number of transduced hepatocytes is approaching that achieved following partial hepatectomy. Furthermore, in a murine model of hereditary tyrosinaemia type 1, Overturf et al 16 demonstrated that when a small number of hepatocytes in a genetically abnormal liver have their genetic deficiency and phenotype corrected, those hepatocytes are subject to a selective growth advantage and replicate to repopulate the liver. Hence the absolute quantity of transduced hepatocytes following one gene transfer procedure may not be as crucial as the safety and repeatability of the procedure.
The lower percentage of transduced cells after T3 treatment compared with partial hepatectomy is probably because the proliferative response following T3 treatment is of lower magnitude and less synchronous. Thus, although T3 treatment results in at least one-third of hepatocytes becoming BrdU positive, at the time of injection of the genetic construct (24 h after T3 injection) only 12.4% of hepatocytes are in S-phase when measured by flash labelling. This is one-third of the number of cells in S-phase at the same time-point after partial hepatectomy. It is therefore likely that repeat administration of the vector during the first 24-72 h after T3 administration will increase the proportion of hepatocytes transduced, and we are currently performing this experiment.
Genes expressed by retroviral vectors are prone to be shut off in vivo over a long time course, and a number of mechanisms may be operating (eg the host cell response to a foreign protein or down-regulation of a foreign promoter). 17 We are currently examining the long-term fate of transduced genes into the liver using this system; preliminary results have identified ␤-galactosidase expressing hepatocytes at greater than 2 months after transduction.
T3 treatment induces hepatocyte proliferation in all lobes of the liver, it is a repeatable method and is simple to use. This method of liver priming before integrative transfection may be suitable for the replacement of genes which encode for the synthetic proteins produced by the liver. Examples of clinical conditions for which this method may have application include the factor VIII and IX gene deficiencies of haemophilia or the LDL receptor gene deficiency of familial hypercholesterolaemia.
